Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mupirocin for Nasal S. aureus Eradication
NCT02284555Phase 4Completed
- Sponsor
- Destiny Pharma
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of mupirocin in Staphylococcus aureus nasal colonization, sponsored by Destiny Pharma. Started Aug 2014; status: completed.
02
Drugs
mupirocin
03
Conditions
Staphylococcus aureus nasal colonization
Beyond the preview
Go deeper on NCT02284555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02284555.